Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

According to the data from the 30-month follow-up, overall survival (OS) rates were 76% for subjects ... for adults with ...

Multiple myeloma is a type of cancer where plasma ... of anemia or kidney failure wasn’t associated with a worsened survival rate. Researchers concluded that the development of bone disease ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

In 1998, the five-year survival rate for multiple myeloma was 34.6%. That means that approximately 35 of 100 people with the disease were alive five years after their diagnosis. By the early 2000s ...

every multiple myeloma diagnosis is unique. Survival statistics can be informative, but they do not provide the entire ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

It was once the standard of care for patients with relapsed or refractory multiple myeloma. Overall response rate (ORR): percentage of patients ... Progression-free survival (PFS): time patients live ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...